We would like to announce the retirement of Tsuyoshi Ogiku, Representative Director, as well as the appointment of Takashi Kiyoizumi to the position of Representative Director and Chief Executive Officer, with effect from August 2, 2024.
*Click here for details

Inaugural Message

I am honored and humbled to succeed Tsuyoshi Ogiku as a new Representative Director/Chief Executive Officer of BTB Therapeutics.
On behalf of the BTB team, I will be committed to expeditiously develop ENDOPIN, a novel non-opioid analgesic molecule, as a safe and effective replacement for opioids, as well as to deliver new therapies to patients with rare genetic diseases and cancer as quickly as possible. I would be very grateful for your continued guidance and support.

Sincerely,

Takashi Kiyoizumi, MD, PhD